WO2022191467A1 - L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 - Google Patents
L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 Download PDFInfo
- Publication number
- WO2022191467A1 WO2022191467A1 PCT/KR2022/002505 KR2022002505W WO2022191467A1 WO 2022191467 A1 WO2022191467 A1 WO 2022191467A1 KR 2022002505 W KR2022002505 W KR 2022002505W WO 2022191467 A1 WO2022191467 A1 WO 2022191467A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zwf
- seq
- csck
- microorganism
- pcj7
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 68
- 150000008575 L-amino acids Chemical class 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 45
- 241000186216 Corynebacterium Species 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 45
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 39
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 36
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 31
- 150000001413 amino acids Chemical group 0.000 claims description 31
- 239000004472 Lysine Substances 0.000 claims description 26
- 229960004799 tryptophan Drugs 0.000 claims description 26
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 claims description 15
- 108090000156 Fructokinases Proteins 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 14
- 235000019766 L-Lysine Nutrition 0.000 claims description 13
- 102000003793 Fructokinases Human genes 0.000 claims description 12
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 10
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 10
- 101710155861 Glucose-6-phosphate 1-dehydrogenase Proteins 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- FRIHGXGYWUWBED-ZLELNMGESA-N (2s)-2,6-bis(azanyl)hexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O FRIHGXGYWUWBED-ZLELNMGESA-N 0.000 claims 1
- PYXDZWUIPFCTJP-XFNAGHOKSA-N (2s)-2-azanyl-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 PYXDZWUIPFCTJP-XFNAGHOKSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 116
- 102000004169 proteins and genes Human genes 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 50
- 101150078419 zwf gene Proteins 0.000 description 45
- 239000013598 vector Substances 0.000 description 43
- 101100174653 Dictyostelium discoideum g6pd-2 gene Proteins 0.000 description 35
- 101150085516 ZWF1 gene Proteins 0.000 description 35
- 108091033319 polynucleotide Proteins 0.000 description 35
- 102000040430 polynucleotide Human genes 0.000 description 35
- 239000002157 polynucleotide Substances 0.000 description 35
- 101150026856 zwf2 gene Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 22
- 101100309698 Escherichia coli cscK gene Proteins 0.000 description 21
- 239000002609 medium Substances 0.000 description 17
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 235000018977 lysine Nutrition 0.000 description 13
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
- 101100533902 Arabidopsis thaliana SPL13A gene Proteins 0.000 description 7
- 101100533904 Arabidopsis thaliana SPL13B gene Proteins 0.000 description 7
- 238000007702 DNA assembly Methods 0.000 description 7
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 7
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 7
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 7
- 101100043227 Oryza sativa subsp. japonica SPL13 gene Proteins 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 6
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- ZIWNLPKLQFDFEU-FJXQXJEOSA-N calcium;3-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid Chemical compound [Ca].OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O ZIWNLPKLQFDFEU-FJXQXJEOSA-N 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013587 production medium Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- -1 aromatic amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 101150013880 cscK gene Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000186248 Corynebacterium callunae Species 0.000 description 2
- 241000446654 Corynebacterium deserti Species 0.000 description 2
- 241001644925 Corynebacterium efficiens Species 0.000 description 2
- 241000291063 Corynebacterium halotolerans Species 0.000 description 2
- 241000128247 Corynebacterium pollutisoli Species 0.000 description 2
- 241000334675 Corynebacterium singulare Species 0.000 description 2
- 241000186249 Corynebacterium sp. Species 0.000 description 2
- 241000186308 Corynebacterium stationis Species 0.000 description 2
- 241000960580 Corynebacterium testudinoris Species 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 101000644386 Brevibacillus parabrevis Phenylalanine racemase [ATP-hydrolyzing] Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101000906861 Chondromyces crocatus ATP-dependent tyrosine adenylase Proteins 0.000 description 1
- 241001605246 Corynebacterium crudilactis Species 0.000 description 1
- 241001134763 Corynebacterium flavescens Species 0.000 description 1
- 241000024402 Corynebacterium imitans Species 0.000 description 1
- 241000158523 Corynebacterium striatum Species 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- GSXOAOHZAIYLCY-HSUXUTPPSA-N keto-D-fructose 6-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O GSXOAOHZAIYLCY-HSUXUTPPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
- C12P13/227—Tryptophan
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01049—Glucose-6-phosphate dehydrogenase (1.1.1.49)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01004—Fructokinase (2.7.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01044—Galacturonokinase (2.7.1.44)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- the present application relates to a microorganism of the genus Corynebacterium that produces L-amino acids, a method for producing L-amino acids using the same, uses for producing L-amino acids, and a composition for producing L-amino acids.
- L-amino acid is a basic structural unit of protein and is used as an important material for pharmaceutical raw materials, food additives, animal feed, nutrients, pesticides, and disinfectants.
- L-lysine is an essential amino acid that is not biosynthesized at all in the body, and is known to be necessary for growth promotion, calcium metabolism, gastric juice secretion promotion, and resistance to disease.
- the L-lysine is variously used in feed, medicine, food, and the like.
- L-tryptophan is also one of the essential amino acids, and is used as a feed additive, infusion, pharmaceutical raw material, and health food material.
- Corynebacterium sp. strain Corynebacterium
- Corynebacterium glutamicum Corynebacterium glutamicum
- a target substance-specific approach such as increasing the expression of a gene encoding an enzyme involved in amino acid biosynthesis or removing a gene unnecessary for amino acid biosynthesis is mainly used ( Korean Patent Publication Nos. 10-0924065, 10-1208480,).
- An object of the present application is to provide a microorganism of the genus Corynebacterium with enhanced activity of glucose-6-phosphate dehydrogenase (Glucose-6-phosphate 1-dehydrogenase) and fructokinase (Fructokinase).
- glucose-6-phosphate dehydrogenase Glucose-6-phosphate 1-dehydrogenase
- fructokinase Fructokinase
- One object of the present application is the activity of glucose-6-phosphate dehydrogenase (Glucose-6-phosphate 1-dehydrogenase) and fructokinase (Fructokinase) is enhanced, Corynebacterium genus to produce L- amino acids to provide microbes.
- glucose-6-phosphate dehydrogenase Glucose-6-phosphate 1-dehydrogenase
- fructokinase Flructokinase
- Another object of the present application is to provide a method for producing L-amino acids using the microorganism.
- Another object of the present application is to provide a use for the production of L-amino acids of the microorganism.
- Another object of the present application is the microorganism; And/or to provide a composition for the production of L- amino acids comprising the culture of the microorganism.
- glucose-6-phosphate dehydrogenase Glucose-6-phosphate 1-dehydrogenase
- fructokinase of the present application is enhanced, and the microorganism producing L-amino acid can produce L-amino acid with high efficiency.
- glucose-6-phosphate dehydrogenase Glucose-6-phosphate 1-dehydrogenase
- fructokinase Fructokinase
- L-amino acid includes all L-amino acids that microorganisms can produce through metabolic processes from various carbon sources, specifically, basic amino acids such as L-lysine, L-arginine, and L-histidine.
- Non-polar amino acids such as , L-valine, L-leucine, L-glycine, L-isoleucine, L-alanine, L-proline, L-methionine, L-serine, L-threonine, L-cysteine, L-aspartic acid, L -Polar amino acids such as glutamine, aromatic amino acids such as L-phenylalanine, L-tyrosine and L-tryptophan, and acidic amino acids such as L-glutamic acid and L-aspartic acid. More specifically, in the present application, the L-amino acid may be L-lysine or L-tryptophan, but is not limited thereto.
- glucose-6-phosphate 1-dehydrogenase (hereinafter, "Zwf") is involved in a metabolic pathway, the pentose phosphate pathway, and glucose 6 - It means that it plays a role in reducing NADP+ to NADPH while oxidizing phosphoric acid.
- the protein may also be referred to as 'G6PD', 'G6PDH', 'glucose-6-phosphate dehydrogenase' or 'Zwf'.
- the gene encoding the protein may be, for example, a zwf gene, but is not limited thereto.
- ' zwf gene' may be used interchangeably with 'gene encoding glucose-6-phosphate dehydrogenase'.
- the protein may be, for example, the same protein as the protein derived from Corynebacterium glutamicum, but is not limited thereto as long as it can increase the production of L-amino acids.
- the Zwf may have the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, or consist of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, or include the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 3 , but not limited thereto.
- the sequence of SEQ ID NO: 1 or SEQ ID NO: 3 can be confirmed in NCBI Genbank, a known database.
- the Zwf may include a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4, but is not limited thereto.
- the sequence of SEQ ID NO: 2 or SEQ ID NO: 4 can be confirmed in NCBI Genbank, a known database.
- the Zwf is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, Or it may be an amino acid sequence having at least 99% homology or identity. In addition, as long as it is an amino acid sequence having such homology or identity and exhibiting a function corresponding to the Zwf, it is apparent that Zwf having an amino acid sequence in which some sequences are deleted, modified, substituted or added is also included within the scope of the present application.
- CscK fructokinase
- the protein may also be referred to as 'fructose phosphorylation enzyme', 'fructokinase', or 'CscK'.
- the gene encoding the protein may be, for example, a csck gene, but is not limited thereto.
- ' csck gene' may be used interchangeably with 'fructokinase-encoding gene'.
- the protein may be, for example, the same protein as the protein derived from Escherichia coli , but is not limited thereto as long as it can increase the production of L-amino acids.
- the CscK may have the amino acid sequence of SEQ ID NO: 5, consist of the amino acid sequence of SEQ ID NO: 5, or include the amino acid sequence set forth in SEQ ID NO: 5, but is not limited thereto.
- the sequence of SEQ ID NO: 5 can be confirmed in NCBI Genbank, a known database.
- the CscK may include a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 6, but is not limited thereto.
- the sequence of SEQ ID NO: 6 can be confirmed in NCBI Genbank, a known database.
- the CscK has at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO: 5 and/or SEQ ID NO: 5 ) or an amino acid sequence having identity.
- it is an amino acid sequence having such homology or identity and exhibiting a function corresponding to the CscK, it is obvious that CscK having an amino acid sequence in which some sequences are deleted, modified, substituted or added is also included within the scope of the present application.
- homology and identity refer to the degree to which two given amino acid sequences or base sequences are related, and may be expressed as a percentage.
- homology and identity can often be used interchangeably.
- Sequence homology or identity of a conserved polynucleotide or polypeptide is determined by standard alignment algorithms, with default gap penalties established by the program used may be used. Substantially, homologous or identical sequences are generally at least about 50%, 60%, 70%, 80% of the entire or full-length sequence under moderate or high stringent conditions. or more than 90% hybrid. Hybridization is also contemplated for polynucleotides containing degenerate codons instead of codons in the polynucleotides.
- Homology or identity to said polypeptide or polynucleotide sequence can be determined, for example, by the algorithm BLAST according to the literature [Karlin and Altschul, Pro. Natl. Acad. Sci. USA, 90, 5873 (1993)], or FASTA by Pearson (Methods Enzymol., 183, 63, 1990). Based on such an algorithm BLAST, a program called BLASTN or BLASTX has been developed (refer to http://www.ncbi.nlm.nih.gov).
- the "microorganism that produces L-amino acids” includes both wild-type microorganisms and microorganisms in which genetic modification has occurred naturally or artificially. Specifically, as a microorganism in which a specific mechanism is weakened or enhanced due to a cause such as insertion of an external gene or intensification or inactivation of the activity of an intrinsic gene, genetic mutation occurs or L-amino acid is produced for the desired L-amino acid production. It may be a microorganism that has enhanced production activity.
- the microorganism producing the L-amino acid is characterized in that the expression or activity of the Zwf and Csck proteins is enhanced, and the desired L-amino acid production ability is increased, and a genetically modified microorganism or recombinant microorganism may be, but is not limited thereto.
- the term "enhancement of activity" of a protein in the present application means that the activity of the protein is increased compared to the intrinsic activity.
- the "intrinsic activity” refers to the activity of a specific protein originally possessed by the parent strain or unmodified microorganism before the transformation when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “pre-modification activity”.
- pre-modification activity When the activity of a protein is "increased” compared to the intrinsic activity, it means that the activity of a specific protein is improved compared to the original activity of the parent strain or the unmodified microorganism before transformation.
- the "increase in activity” may be achieved by introducing an exogenous protein or enhancing the activity of an intrinsic protein, but specifically, it may be achieved through enhancing the activity of an intrinsic protein. Whether the activity of the protein is enhanced can be confirmed from the increase in the level of activity, expression, or the amount of product produced from the protein.
- the enhancement of the activity can be applied by various methods well known in the art, and is not limited as long as it can enhance the activity of the target protein compared to the microorganism before modification. Specifically, it may be one using genetic engineering and/or protein engineering well known to those skilled in the art, which is a routine method of molecular biology, but is not limited thereto (eg, Sitnicka et al. Functional Analysis of Genes. Advances in Cell). Biology 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).
- the protein to be the target of the activity enhancement that is, the target protein may be Zwf and Csck, but is not limited thereto.
- the protein activity enhancement of the present application is,
- modification of the polynucleotide sequence encoding the protein to enhance protein activity eg, modification of the gene sequence encoding the protein to encode the modified protein to enhance activity
- It may be a combination of two or more selected from 1) to 8), but is not limited thereto.
- the increase in the intracellular copy number of the gene encoding the protein is performed by any method known in the art, for example, the gene encoding the protein is cloned and functions independently of the host, to which the gene encoding the protein is operably linked. It can be carried out by introducing a vector capable of it into a host cell. Alternatively, a vector capable of inserting the gene into a chromosome in the host cell, to which the gene is operably linked, may be introduced into the host cell, but is not limited thereto.
- the term "vector” refers to a DNA preparation containing a polynucleotide sequence encoding a target protein in a suitable host in a form operably linked to regulatory sequences suitable for expressing the target protein.
- the expression control sequence may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation.
- the vector After transformation into an appropriate host cell, the vector can replicate or function independently of the host genome, and can be integrated into the genome itself.
- the vector used in the present application is not particularly limited, and any vector known in the art may be used.
- Examples of commonly used vectors include plasmids, cosmids, viruses and bacteriophages in a natural or recombinant state.
- pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A may be used as phage vectors or cosmid vectors, and pDZ-based, pBR-based, and pUC-based plasmid vectors may be used.
- pBluescript II-based pGEM-based, pTZ-based, pCL-based, pET-based and the like
- pDZ pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors and the like
- pC1BAC vectors and the like can be used.
- the term "transformation” refers to introducing a recombinant vector including a polynucleotide encoding a target protein into a host cell so that the protein encoded by the polynucleotide can be expressed in the host cell.
- the transformed polynucleotide it may include all of them regardless of whether they are inserted into the chromosome of the host cell or located outside the chromosome.
- the transformation method includes any method of introducing a nucleic acid into a cell, and may be performed by selecting a suitable standard technique as known in the art depending on the host cell.
- operably linked means that the polynucleotide sequence is functionally linked to a promoter sequence or expression control region that initiates and mediates transcription of the polynucleotide encoding the target protein of the present application. do.
- the operable linkage may be prepared using a genetic recombination technique known in the art, and site-specific DNA cleavage and ligation may be made using a cleavage and ligation enzyme in the art, but is not limited thereto.
- the method of replacing a gene expression control sequence on a chromosome encoding a protein with a sequence with strong activity is any method known in the art, for example, a nucleic acid sequence is deleted to further enhance the activity of the expression control sequence. , insertion, non-conservative or conservative substitution, or a combination thereof by inducing a mutation in the sequence, or by replacing the nucleic acid sequence with a stronger activity.
- the expression control sequence is not particularly limited thereto, but may include a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence for regulating the termination of transcription and translation.
- the method may specifically be to link a strong heterologous promoter instead of the original promoter, but is not limited thereto.
- Examples of known strong promoters include CJ1 to CJ7 promoters (US Pat. No. 7662943 B2), lac promoter, Trp promoter, trc promoter, tac promoter, lambda phage PR promoter, PL promoter, tet promoter and rmf promoter. It is not limited thereto, and includes any substitution with a promoter that is stronger than the intrinsic activity.
- the base sequence modification of the start codon or 5'-UTR region of the gene transcript encoding the protein is performed by any method known in the art, for example, the intrinsic start codon of the protein is compared to the intrinsic start codon. It may be substituted with another start codon having a higher protein expression rate, but is not limited thereto.
- Modification of the amino acid sequence or polynucleotide sequence of 4) and 5) above can be performed by any method known in the art, for example, by deleting, inserting, non-conservative or It can be carried out by inducing a mutation in the expression control sequence by conservative substitution or a combination thereof, or by replacing the polynucleotide sequence with an improved polynucleotide sequence to have stronger activity.
- the replacement may specifically be to insert the gene into the chromosome by homologous recombination, but is not limited thereto.
- the vector used may further include a selection marker for confirming whether or not the chromosome is inserted.
- the selection marker is used to select cells transformed with the vector, that is, to determine whether the gene to be introduced is inserted, and selectable phenotypes such as drug resistance, auxotrophy, resistance to cytotoxic agents, or surface protein expression. Markers to be given may be used, but the present invention is not limited thereto. In an environment treated with a selective agent, only cells expressing a selectable marker survive or exhibit other expression traits, and thus transformed cells can be selected.
- the introduction of the foreign polynucleotide exhibiting the activity of the protein may be performed by any method known in the art, for example, a foreign polynucleotide encoding a protein exhibiting the same/similar activity as the protein, or a codon-optimized mutation thereof It can be carried out by introducing the type polynucleotide into a host cell.
- the foreign polynucleotide may be used without limitation in origin or sequence as long as it exhibits the same/similar activity as the protein.
- the introduced foreign polynucleotide may be introduced into the host cell by optimizing its codon so that the optimized transcription and translation are performed in the host cell.
- the introduction can be performed by appropriately selecting a known transformation method by those skilled in the art, and the introduced polynucleotide is expressed in a host cell to generate a protein and increase its activity.
- Codon optimization of the polynucleotide encoding the protein is codon-optimized so that the transcription or translation of the endogenous polynucleotide is increased in the host cell, or the transcription and translation of the foreign polynucleotide is optimized in the host cell. It may be that its codons are optimized so that the
- Selecting an exposed site by analyzing the tertiary structure of the protein and modifying or chemically modifying it for example, compares the sequence information of the polypeptide to be analyzed with a database in which sequence information of known proteins is stored to determine the degree of sequence similarity. Accordingly, it may be to determine a template protein candidate, check the structure based on this, and select an exposed site to be modified or chemically modified and modified or modified.
- Such protein activity enhancement may be that the activity or concentration of the corresponding protein is increased based on the activity or concentration of the protein expressed in the wild-type or pre-modified microbial strain, or the amount of product produced from the protein is increased.
- the present invention is not limited thereto.
- the term "pre-transformation strain” or "pre-transformation microorganism” does not exclude a strain containing a mutation that can occur naturally in a microorganism, it is a natural strain itself, or a genetic variation caused by an artificial factor. This means the strain before the change.
- the transformation may be enhancement of PheA activity.
- pre-modified strain or “pre-modified microorganism” may be used interchangeably with “unmutated strain”, “unmodified strain”, “unmodified microorganism”, “unmodified microorganism” or “reference microorganism”.
- the reference microorganism is not particularly limited as long as it is a microorganism that produces L-amino acids, and mutant strains with enhanced L-amino acid production ability compared to the wild type are also included without limitation.
- Corynebacterium glutamicum KCCM11016P (Korean Patent No. 10-0159812), KCCM10770P (Korean Patent No. 10-0924065), CJ3P (Binder et al. Genome Biology 2012, 13: R40) strain or L-tryptophan-producing Corynebacterium glutamicum KCCM12218P (Korean Patent No. 10-2035844) strain in which one or more genetic modifications are added to the strain to enhance the biosynthetic pathway may be included, but is not limited thereto.
- the microorganism producing the L-amino acid is any microorganism capable of producing L-amino acid by enhancing Zwf and Csck activity by the above-described method.
- the "microorganism that produces L-amino acids” may be used interchangeably with “microorganisms producing L-amino acids” and “microorganisms having L-amino acid production ability", and specifically may be microorganisms of the genus Corynebacterium, but , but not limited thereto.
- microorganisms of the genus Corynebacterium may include all microorganisms of the genus Corynebacterium. Specifically, Corynebacterium glutamicum ( Corynebacterium glutamicum ), Corynebacterium crudilactis ), Corynebacterium deserti ( Corynebacterium deserti ), Corynebacterium efficiens ( Corynebacterium efficiens ) , Corynebacterium callunae ( Corynebacterium callunae ), Corynebacterium stationis ( Corynebacterium stationis ), Corynebacterium singulare ( Corynebacterium singulare ), Corynebacterium halo Tolerans ( Corynebacterium halotolerans ), Corynebacterium Lium striatum ( Corynebacterium striatum ), Corynebacterium ammoniagenes ), Corynebacterium
- microorganisms of the genus Corynebacterium can produce L-amino acids, but their production capacity is remarkably low, and neither genes nor mechanism principles acting on the production mechanism have been identified. Therefore, the 'microorganism of the genus Corynebacterium that produces L-amino acids' of the present application enhances or inactivates the activity of the natural wild-type microorganism itself, the gene related to the L-amino acid production mechanism, to have improved L-amino acid production ability.
- Corynebacterium refers to a microorganism of the genus Corynebacterium, or a microorganism of the genus Corynebacterium having improved L-amino acid production ability by introducing or enhancing the activity of an external gene.
- the present application is another aspect, comprising the steps of culturing the microorganism according to the present application in a medium; And it provides a method for producing L- amino acids, comprising the step of recovering L- amino acids from the microorganism or medium.
- microorganism according to the present application is as described above.
- any culture conditions and culture methods known in the art may be used for the culturing of microorganisms of the genus Corynebacterium.
- the term "cultivation” means growing microorganisms in an appropriately artificially controlled environmental condition.
- the method of culturing L-amino acid using a microorganism producing L-amino acid may be performed using a method widely known in the art. Specifically, the culture may be continuously cultured in a batch process, an injection batch or a repeated fed batch process, but is not limited thereto. The medium used for culture should meet the requirements of the particular strain in an appropriate way. Culture media for Corynebacterium strains are known (eg, Manual of Methods for General Bacteriology by the American Society for Bacteriology, Washington D.C., USA, 1981).
- Carbon sources that can be used in the medium include sugars and carbohydrates such as glucose, saccharose, lactose, fructose, maltose, starch, cellulose, oils and fats such as soybean oil, sunflower oil, castor oil, coconut oil, palmitic acid, stearic acid , fatty acids such as linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid. These materials may be used individually or as a mixture, but are not limited thereto.
- Nitrogen sources that may be used include peptone, yeast extract, broth, malt extract, corn steep liquor, soybean wheat and urea or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate.
- the nitrogen source may also be used individually or as a mixture, but is not limited thereto.
- the phosphorus contained in the medium may include potassium dihydrogen phosphate or dipotassium hydrogen phosphate or a salt containing the corresponding sodium.
- the culture medium may contain a metal salt such as magnesium sulfate or iron sulfate necessary for growth.
- essential growth substances such as amino acids and vitamins can be used.
- precursors suitable for the culture medium may be used. The above-mentioned raw materials may be added in a batch or continuous manner by an appropriate method to the culture during the culture process, but is not limited thereto.
- a basic compound such as sodium hydroxide, potassium hydroxide, ammonia, or an acid compound such as phosphoric acid or sulfuric acid may be used in an appropriate manner to adjust the pH of the culture.
- an antifoaming agent such as a fatty acid polyglycol ester may be used to inhibit the formation of bubbles.
- Oxygen or oxygen-containing gas eg, air
- the temperature of the culture may be usually 20 °C to 45 °C, specifically 25 °C to 40 °C.
- the incubation time may be continued until a desired amount of L-amino acid is obtained, but specifically, it may be 10 to 160 hours. However, it is not limited to these examples.
- the present application may additionally include a step of preparing a medium before the step of culturing in the method of the present application, but is not limited thereto.
- Isolation of L-amino acids from the culture can be accomplished by conventional methods known in the art.
- separation method methods such as centrifugation, filtration, chromatography and crystallization may be used.
- a supernatant obtained by removing the biomass by centrifuging the culture at low speed may be separated through ion exchange chromatography, but is not limited thereto.
- the recovery step may include a purification process, and may be performed using a suitable method known in the art.
- the present application provides a use for producing L-amino acids of the microorganism according to the present application.
- microorganism and L-amino acid according to the present application are as described above.
- the present application is another aspect, the microorganism according to the present application; And/or it provides a composition for the production of L- amino acids comprising the culture of the microorganism.
- microorganism and L-amino acid according to the present application are as described above.
- Example 1-1 Corynebacterium glutamicum ( Corynebacterium glutamicum ) Construction of a vector in which the glucose-6-phosphate dehydrogenase gene (zwf) derived from ATCC13032 is enhanced
- the enhancement of the gene is the SPL13 promoter (US 10584338 B2) in the transposon of Corynebacterium glutamicum ATCC13032, respectively, and the CJ7 promoter derived from Corynebacterium ammoniagenes ( US 7662943 B2 ) The effect was confirmed by putting zwf connected to .
- zwf was Corynebacterium glutamicum ATCC13032 genomic DNA as a template, respectively, based on NCBI nucleotide sequence (NC_003450.3) information of SEQ ID NOs: 9, 10 (Table 1) and SEQ ID NOs: 13, 14 (Table 2)
- NCBI nucleotide sequence NCBI nucleotide sequence
- SEQ ID NOs: 9, 10 Table 1
- SEQ ID NOs: 13, 14 Table 2
- a primer containing a polynucleotide was prepared and PCR (SolgTM Pfu-X DNA polymerase) was performed under the conditions shown in Table 4 to obtain a zwf gene fragment for constructing a vector.
- pDZTn-Pcj7-zwf (C.gl13032) primer sequence No. designation DNA sequence SEQ ID NO: 11 primer 5 GCAGAAGGAATGAGTTCCTCagaaacatcccagcgctact SEQ ID NO: 12 primer 6 gagtgtttcctttcgttgggtac SEQ ID NO: 13 primer 7 cccaacgaaaggaacactcGTGAGCACAAACACG SEQ ID NO: 14 primer 8 GTTATTAGATGTCGGGCCCATTATGGCCTCGCGCCAGGTGT
- SEQ ID NOs: 7 and 8 (Table 1), SEQ ID NOs: 11 and 12 (Table 2) primers were used and PCR (SolgTM Pfu-X DNA polymerase) was performed.
- Table 4 Amplified SPL13, CJ7 promoter region, zwf gene fragment, and vector pDZTn (US Pat. No. 8932861 B2) digested with ScaI restriction enzyme was prepared by Gibson assembly (DG Gibson et al., NATURE METHODS, VOL. 6 NO.5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix) was used to connect, transforming E.
- Plasmids were obtained from the selected colonies using a commonly known plasmid extraction method, and the plasmids were named pDZTn-Pspl13-zwf (C.gl13032) and pDZTn-Pcj7-zwf (C.gl13032).
- Example 1-2 Construction of a vector in which the glucose-6-phosphate dehydrogenase gene (zwf) derived from Corynebacterium glutamicum ATCC13869 is enhanced
- Corynebacterium glutamicum ATCC13869-derived zwf strengthening effect was confirmed by using Corynebacterium glutamicum ATCC13869 genomic DNA as a template, respectively, and Corynebacterium glutamicum registered in the US National Institutes of Health (NIH GenBank). Based on the information on the cum ATCC13869 gene and surrounding nucleotide sequences, primers containing polynucleotides of SEQ ID NOs: 17 and 18 (Table 5) and SEQ ID NOs: 21, 22 (Table 6) were prepared and PCR (SolgTM) under the conditions of Table 4 Pfu-X DNA polymerase) to obtain a zwf gene fragment to construct a vector.
- pDZTn-Pspl13-zwf (C.gl13869) primer sequence No. designation DNA sequence SEQ ID NO: 15 primer 9 GCAGAAGGAATGAGTTCCTCGGCGCTTCATGTCAACAATC SEQ ID NO: 16 primer 10 tgttttgatctcctccaataatc SEQ ID NO: 17 primer 11 tattggaggagatcaaacaGTGAGCACAAACACG SEQ ID NO: 18 primer 12 GTTATTAGATGTCGGGCCCATTATGGCCTCGCGCCAGGTGT
- SPL13 promoter and the CJ7 promoter derived from Corynebacterium ammoniagenes SEQ ID NOs: 15 and 16 (Table 5), SEQ ID NOs: 19 and 20 (Table 6) primers were used, and PCR (SolgTM Pfu- X DNA polymerase) was performed.
- Amplified SPL13, CJ7 promoter region, zwf gene fragment, and vector pDZTn (US Pat. No. 8932861 B2) digested with ScaI restriction enzyme was synthesized by Gibson assembly (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009). , NEBuilder HiFi DNA Assembly Master Mix) after ligation, transformed into E. coli DH5 ⁇ and plated on LB solid medium containing kanamycin (25 mg/l). In order to select colonies transformed with the vector linking the desired gene and pDZTn, PCR was performed with primers of SEQ ID NOs: 47 and 48 (Table 3).
- Plasmids were obtained from the selected colonies using a commonly known plasmid extraction method, and these plasmids were named pDZTn-Pspl13-zwf (C.gl13869) and pDZTn-Pcj7-zwf (C.gl13869).
- Escherichia coli Echerichia coli
- cscK gene information was obtained from NCBI's Echerichia coli W (CP002967), and based on this, SEQ ID NOs: 25 and 26 (Table 7), SEQ ID NOs: 29 and 30 (Table 8) containing polynucleotides
- a cscK gene fragment for preparing a vector was obtained by preparing a primer and performing PCR (SolgTM Pfu-X DNA polymerase) under the conditions shown in Table 4.
- SEQ ID NOs: 23 and 24 (Table 7), SEQ ID NOs: 27 and 28 (Table 8) primers were used, and PCR (SolgTM Pfu-X DNA polymerase) was performed under the conditions of Table 4.
- the amplified SPL13, CJ7 promoter region, cscK (E.co) gene fragment, and vector pDZTn (US Patent No. 8932861 B2) digested with ScaI restriction enzyme was converted to Gibson assembly (DG Gibson et al., NATURE METHODS, VOL.6 NO). .5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix) after ligation, transformed into E. coli DH5 ⁇ and plated on LB solid medium containing kanamycin (25 mg/l).
- PCR was performed with primers of SEQ ID NOs: 47 and 48 (Table 3).
- Plasmids were obtained from the selected colonies using a commonly known plasmid extraction method, and the plasmids were named pDZTn-Pspl13-cscK (E.co) and pDZTn-Pcj7-cscK (E.co).
- Examples 1-4 Construction of a vector enhanced with zwf derived from Corynebacterium glutamicum ATCC13032 and cscK derived from Escherichia coli
- Example 1-1 By confirming the individual gene enhancing effect of Example 1-1 and Example 1-3, a vector was prepared to confirm the simultaneous strengthening effect of the two genes.
- a plasmid was obtained from the selected colony using a commonly known plasmid extraction method, and the plasmid was named pDZTn-Pspl13-zwf(C.gl13032)_Pcj7-cscK(E.co).
- a plasmid was obtained from the selected colony using a commonly known plasmid extraction method, and the plasmid was named pDZTn-Pcj7-zwf(C.gl13032)_Pspl13-cscK(E.co).
- a plasmid was obtained from the selected colony using a commonly known plasmid extraction method, and the plasmid was named pDZTn-Pspl13-zwf(C.gl13869)_Pcj7-cscK(E.co).
- a plasmid was obtained from the selected colony using a commonly known plasmid extraction method, and this plasmid was named pDZTn-Pcj7-zwf(C.gl13869)_Pspl13-cscK(E.co).
- Example 2-1 Production of a lysine-producing strain with enhanced zwf derived from Corynebacterium glutamicum ATCC13032
- Corynebacterium glutamicum KCCM11016P (Korea) for producing L-lysine using the pDZTn-Pspl13-zwf (C.gl13032) and pDZTn-Pcj7-zwf (C.gl13032) vectors prepared in Example 1-1, respectively.
- Registered Patent No. 10-0159812), KCCM10770P (Korean Patent No. 10-0924065), and CJ3P (Binder et al. Genome Biology 2012, 13:R40) strains were electroporated (Appl. Microbiol. Biotechnol.
- Example 2-2 Preparation of a tryptophan-producing strain with enhanced zwf derived from Corynebacterium glutamicum ATCC13869
- Corynebacterium glutamicum KCCM12218P for producing L-tryptophan using the pDZTn-Pspl13-zwf (C.gl13869) and pDZTn-Pcj7-zwf (C.gl13869) vectors prepared in Example 1-2, respectively Registered Patent No. 10-2035844)
- Pspl13-zwf C.gl13869
- Pcj7-zwf C.gl13869
- the strain thus obtained was named Corynebacterium glutamicum KCCM12218P_Pspl13-zwf (C.gl13869) and KCCM12218P_Pcj7-zwf (C.gl13869).
- Example 2-3 Production of Escherichia coli-derived cscK-enhanced lysine and tryptophan-producing strains
- Corynebacterium glutamicum KCCM11016P (Korea) for producing L-lysine using the pDZTn-Pspl13-cscK (E.co) and pDZTn-Pcj7-cscK (E.co) vectors prepared in Example 1-3, respectively Registered Patent No. 10-0159812), KCCM10770P (Korean Patent No. 10-0924065), CJ3P (Binder et al. Genome Biology 2012, 13:R40) strains and Corynebacterium glutamicum producing L-tryptophan After transforming the KCCM12218P (Korean Patent No. 10-2035844) strain by electroporation (Appl. Microbiol.
- the lysine-producing strain thus obtained is Corynebacterium glutamicum KCCM11016P_Pspl13-cscK (E.co), KCCM11016P_Pcj7-cscK (E.co), KCCM10770P_Pspl13-cscK (E.co), KCCM10770P_Pcj7-cscK (E.co), CJ3P_Pspl13-cscK (E.co) and CJ3P_Pcj7-cscK (E.co) were named, and tryptophan-producing strains were named KCCM12218P_Pspl13-cscK (E.co), KCCM12218P_Pcj7-cscK (E.co).
- Example 2-4 Preparation of lysine-producing strains with enhanced zwf and Escherichia coli-derived cscK derived from Corynebacterium glutamicum ATCC13032
- the obtained strain was Corynebacterium glutamicum KCCM11016P_Pspl13-zwf(C.gl13032)_Pcj7-cscK(E.co), KCCM11016P_Pcj7-zwf(C.gl13032)_Pspl13-cscK(E.co), KCCM10770P_Pspl13-zwf (C.gl13032)_Pcj7-cscK(E.co), KCCM10770P_Pcj7-zwf(C.gl13032)_Pspl13-cscK(E.co), CJ3P_Pspl13-zwf(C.gl13032)_Pcj7-cscK(E.co), CJ3P_Pcj7 It was named zwf(C.gl13032)_Pspl13-cscK(E.co).
- Example 2-5 Preparation of tryptophan-producing strains with enhanced zwf and Escherichia coli-derived cscK derived from Corynebacterium glutamicum ATCC13869
- Pspl13-zwf(C.gl13869)_Pcj7-cscK(E.co) and Pcj7-zwf(C.gl13869)_Pspl13-cscK(E.co) were inserted between the transposon genes through a secondary crossover process.
- strains were obtained.
- PCR and sequencing were performed using primers (Table 3) of SEQ ID NO: 47 and SEQ ID NO: 48 that can amplify adjacent regions including the position at which the gene was inserted, and the corresponding genetic manipulation was confirmed.
- the tryptophan-producing strain thus obtained was named Corynebacterium glutamicum KCCM12218P_Pspl13-zwf(C.gl13869)_Pcj7-cscK(E.co), KCCM12218P_Pcj7-zwf(C.gl13869)_Pspl13-cscK(E.co). .
- Example 3-1 Corynebacterium glutamicum ATCC13032-derived zwf, Escherichia coli-derived cscK-enhanced strain L-lysine-producing ability comparison
- each strain was inoculated into a 250 ml corner-baffle flask containing 25 ml of a seed medium, and cultured with shaking at 30° C. for 20 hours at 200 rpm.
- a 250 ml corner-baffle flask containing 24 ml of production medium was inoculated with 1 ml of the seed culture and incubated at 37° C. for 42 hours, shaking at 200 rpm.
- the production of L-lysine was measured by HPLC. The experiment was repeated 3 times, and the culture results (average values) are shown in Tables 13, 14, and 15.
- Raw sugar 45 g (NH4)2SO4 15 g, soy protein 10 g, molasses 10 g, KH2PO4 0.55 g, MgSO4 7H2O 0.6 g, biotin 0.9 mg, thiamine hydrochloride 4.5 mg, calcium-pantothenic acid 4.5 mg, nicotinamide 30 mg, MnSO4 9 mg, FeSO4 9 mg, ZnSO4 0.45 mg, CuSO4 0.45 mg, CaCO3 30 g (based on 1 liter of distilled water).
- the prepared zwf (C.gl13032), cscK (E.co) single-enhanced or simultaneous-enhanced lysine-producing strains confirmed the effect of improving the yield by 1.2 to 2.6%P compared to the parent strain KCCM11016P, as shown in Table 13 below. Since 4 mol of NADPH is required to produce 1 mol of lysine in Corynebacterium, an increase in NADPH supply capacity in a lysine-producing strain is closely related to an increase in yield (Kjeld Raunkjaer Kjeldsen at el., Biotechnol. Bioeng., 2009 Feb 1 ;102(2):583-97.).
- the ability to supply NADPH was improved by enhancing the zwf gene alone in the KCCM1016P strain, thereby confirming the effect of improving production by 0.9g/L.
- the cscK(E.co) gene was introduced so that the fructose inside the cell generated when the raw sugar of Corynebacterium was used could be directly used, and the improvement effect of 2.1/L increased by 15.2% compared to the parent strain KCCM11016P was confirmed.
- the reducing power supply ability through the zwf gene is maximized, and the effect of improving the lysine yield is significantly increased compared to the single enhancement.
- the reinforcing effect of the gene showed the same effect in other lysine-producing strains KCCM10770P and CJ3P as shown in Tables 14 and 15.
- zwf (C.gl13032) and cscK (E.co) were strengthened at the same time compared to the single-enhanced strains, 22.1% and 27.1% increased production compared to the parent strain, respectively, 1.9g/L and 1.6g/L improved results.
- Example 3-2 Comparison of L-tryptophan-producing ability of zwf derived from Corynebacterium glutamicum ATCC13869 and cscK-enhanced strain derived from Escherichia coli
- the KCCM12218P-based cscK(E.co)-enhanced strain prepared in 3 was cultured in the following manner, respectively, and the cell mass, glucose consumption, and tryptophan production capacity were compared.
- each strain was inoculated into a 250 ml corner-baffle flask containing 25 ml of a seed medium, and cultured with shaking at 30° C. for 20 hours at 200 rpm.
- a 250 ml corner-baffle flask containing 24 ml of production medium was inoculated with 1 ml of the seed culture and incubated at 37° C. for 42 hours, shaking at 200 rpm.
- the production of L-tryptophan was measured by HPLC. The experiment was repeated 3 times, and the culture results (average values) are shown in Table 16.
- Raw sugar 30g (NH4)2SO4 15 g, MgSO4 7H2O 1.2 g, KH2PO4 1 g, yeast extract 5 g, biotin 900 ⁇ g, thiamine hydrochloride 4500 ⁇ g, calcium-pantothenic acid 4500 ⁇ g, CaCO3 30 g (based on 1 liter of distilled water).
- the enhancement of the tryptophan yield due to the expression of the zwf gene improved the intracellular concentrations of PRPP and E4P, which are used as precursors of tryptophan.
- the tryptophan yield improving factors were integrated, and the production of tryptophan was improved by 34% to 45% compared to the parent strain KCCM12218P, and the two genes were significantly enhanced compared to when the two genes were enhanced alone. An improved tryptophan yield was confirmed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
No. | 명칭 | DNA 서열 |
서열번호 7 | primer 1 | GCAGAAGGAATGAGTTCCTCGGCGCTTCATGTCAACAATC |
서열번호 8 | primer 2 | tgttttgatctcctccaataatc |
서열번호 9 | primer 3 | tattggaggagatcaaaacaGTGAGCACAAACACG |
서열번호 10 | primer 4 | GTTATTAGATGTCGGGCCCATTATGGCCTGCGCCAGGTGT |
No. | 명칭 | DNA 서열 |
서열번호 11 | primer 5 | GCAGAAGGAATGAGTTCCTCagaaacatcccagcgctact |
서열번호 12 | primer 6 | gagtgtttcctttcgttgggtac |
서열번호 13 | primer 7 | cccaacgaaaggaaacactcGTGAGCACAAACACG |
서열번호 14 | primer 8 | GTTATTAGATGTCGGGCCCATTATGGCCTGCGCCAGGTGT |
No. | 명칭 | DNA 서열 |
서열번호 47 | primer 41 | ACGACGCTGGTATTTCTCCC |
서열번호 48 | primer 42 | TGATTGTCGATATGACCGGG |
단계 | 온도 | 시간 |
Initialization | 95℃ | 10분 |
Denaturation | 95℃ | 30초 |
Annealing | 62℃ | 30초 |
Elongation | 72℃ | 1~2분 |
Post Elongation | 72℃ | 5분 |
No. | 명칭 | DNA 서열 |
서열번호 15 | primer 9 | GCAGAAGGAATGAGTTCCTCGGCGCTTCATGTCAACAATC |
서열번호 16 | primer 10 | tgttttgatctcctccaataatc |
서열번호 17 | primer 11 | tattggaggagatcaaaacaGTGAGCACAAACACG |
서열번호 18 | primer 12 | GTTATTAGATGTCGGGCCCATTATGGCCTGCGCCAGGTGT |
No. | 명칭 | DNA 서열 |
서열번호 19 | primer 13 | GCAGAAGGAATGAGTTCCTCagaaacatcccagcgctact |
서열번호 20 | primer 14 | gagtgtttcctttcgttgggtac |
서열번호 21 | primer 15 | cccaacgaaaggaaacactcGTGAGCACAAACACG |
서열번호 22 | primer 16 | GTTATTAGATGTCGGGCCCATTATGGCCTGCGCCAGGTGT |
No. | 명칭 | DNA 서열 |
서열번호 23 | primer 17 | GCAGAAGGAATGAGTTCCTCGGCGCTTCATGTCAACAATC |
서열번호 24 | primer 18 | tgttttgatctcctccaataatc |
서열번호 25 | primer 19 | tattggaggagatcaaaacaATGTCAGCCAAAGTA |
서열번호 26 | primer 20 | GTTATTAGATGTCGGGCCCACTATTCCAGTTCTTGTCGAC |
No. | 명칭 | DNA 서열 |
서열번호 27 | primer 21 | GCAGAAGGAATGAGTTCCTCagaaacatcccagcgctact |
서열번호 28 | primer 22 | gagtgtttcctttcgttgggtac |
서열번호 29 | primer 23 | cccaacgaaaggaaacactcATGTCAGCCAAAGTATGGGT |
서열번호 30 | primer 24 | GTTATTAGATGTCGGGCCCACTATTCCAGTTCTTGTCGAC |
No. | 명칭 | DNA 서열 |
서열번호 31 | primer 25 | GCAGAAGGAATGAGTTCCTCGGCGCTTCATGTCAACAATC |
서열번호 32 | primer 26 | ggatgtttctTTATGGCCTGCGCCA |
서열번호33 | primer 27 | CAGGCCATAAagaaacatcccagcg |
서열번호 34 | primer 28 | GTTATTAGATGTCGGGCCCACTATTCCAGTTCTTGTCGAC |
No. | 명칭 | DNA 서열 |
서열번호 35 | primer 29 | GCAGAAGGAATGAGTTCCTCagaaacatcccagcgctact |
서열번호 36 | primer 30 | atgaagcgccTTATGGCCTGCGCCA |
서열번호 37 | primer 31 | CAGGCCATAAggcgcttcatgtcaa |
서열번호 38 | primer 32 | GTTATTAGATGTCGGGCCCACTATTCCAGTTCTTGTCGAC |
No. | 명칭 | DNA 서열 |
서열번호 39 | primer 33 | GCAGAAGGAATGAGTTCCTCGGCGCTTCATGTCAACAATC |
서열번호 440 | primer 34 | ggatgtttctTTATGGCCTGCGCCA |
서열번호 41 | primer 35 | CAGGCCATAAagaaacatcccagcg |
서열번호 42 | primer 36 | GTTATTAGATGTCGGGCCCACTATTCCAGTTCTTGTCGAC |
No. | 명칭 | DNA 서열 |
서열번호 43 | primer 37 | GCAGAAGGAATGAGTTCCTCagaaacatcccagcgctact |
서열번호 44 | primer 38 | atgaagcgccTTATGGCCTGCGCCA |
서열번호 45 | primer 39 | CAGGCCATAAggcgcttcatgtcaa |
서열번호 46 | primer 40 | GTTATTAGATGTCGGGCCCACTATTCCAGTTCTTGTCGAC |
균 주 | OD562 | 소모당(g/L) | 라이신 생산량(g/L) | 모균주 대비 (%) |
KCCM11016P | 45.6 | 50 | 13.8 | 100 |
KCCM11016P_Pspl13-zwf(C.gl13032) | 46.1 | 50 | 14.7 | 106.5 |
KCCM11016P_Pcj7-zwf(C.gl13032) | 46.7 | 50 | 14.5 | 105.1 |
KCCM11016P_Pspl13-cscK(E.co) | 45.8 | 50 | 14.4 | 104.3 |
KCCM11016P_Pcj7-cscK(E.co) | 46.4 | 50 | 14.4 | 104.3 |
KCCM11016P_ Pspl13-zwf(C.gl13032)_Pcj7-cscK(E.co) | 46.3 | 50 | 15.9 | 115.2 |
KCCM11016P_ Pcj7-zwf(C.gl13032)_Pspl13-cscK(E.co) | 45.9 | 50 | 15.6 | 113.0 |
균 주 | OD562 | 소모당 (g/L) |
라이신 생산량 (g/L) | 모균주 대비 (%) |
KCCM10770P | 63.3 | 50 | 8.6 | 100% |
KCCM10770P_Pspl13-zwf(C.gl13032) | 60.1 | 50 | 9.2 | 107.0% |
KCCM10770P_Pcj7-zwf(C.gl13032) | 61.5 | 50 | 9 | 104.7% |
KCCM10770P_Pspl13-cscK(E.co) | 65.5 | 50 | 9.1 | 105.8% |
KCCM10770P_Pcj7-cscK(E.co) | 66.1 | 50 | 9.4 | 109.3% |
KCCM10770P_ Pspl13-zwf(C.gl13032)_Pcj7-cscK(E.co) | 64.9 | 50 | 10.5 | 122.1% |
KCCM10770P_ Pcj7-zwf(C.gl13032) _Pspl13-cscK(E.co) | 64.1 | 50 | 10.2 | 118.6% |
균 주 | OD562 | 소모당 (g/L) |
라이신 생산량 (g/L) | 모균주 대비 (%) |
CJ3P | 48.8 | 50 | 5.9 | 100% |
CJ3P_ Pspl13-zwf(C.gl13032) | 46.7 | 50 | 6.4 | 108.5% |
CJ3P_Pcj7-zwf(C.gl13032) | 46.5 | 50 | 6.3 | 106.8% |
CJ3P_Pspl13-cscK(E.co) | 50.1 | 50 | 6.1 | 103.4% |
CJ3P_Pcj7-cscK(E.co) | 48.6 | 50 | 6.6 | 111.9% |
CJ3P_Pspl13-zwf(C.gl13032)Pcj7-cscK(E.co) | 49.4 | 50 | 7.5 | 127.1% |
CJ3P_Pcj7_zwf(C.gl13032)_Pspl13-cscK(E.co) | 50.3 | 50 | 7.2 | 122.0% |
균 주 | OD562 | 소모당 (g/L) | 트립토판 생산량 (g/L) |
모균주 대비 (%) |
KCCM12218P | 69.7 | 30 | 2.15 | 100 |
KCCM12218P_Pspl13-zwf(C.gl13869) | 64.1 | 30 | 2.33 | 108.4 |
KCCM12218P_Pcj7-zwf(C.gl13869) | 68.5 | 30 | 2.32 | 107.9 |
KCCM12218P _Pspl13-cscK(E.co) | 61.9 | 30 | 2.65 | 123.3 |
KCCM12218P_Pcj7-cscK(E.co) | 62.1 | 30 | 2.44 | 113.5 |
KCCM12218P_Pspl13_zwf(C.gl13869)_Pcj7-cscK(E.co) | 61.1 | 30 | 2.89 | 134.4 |
KCCM12218P_Pcj7_zwf(C.gl13869)_Pspl13-cscK(E.co) | 59.8 | 30 | 3.12 | 145.1 |
Claims (10)
- 글루코스-6-포스페이트 디하이드로게나제(Glucose-6-phosphate 1-dehydrogenase) 및 프럭토키나제(Fructokinase)의 활성이 강화된, L-아미노산을 생산하는 코리네박테리움 속 미생물.
- 제1항에 있어서, 상기 글루코스-6-포스페이트 디하이드로게나제는 서열번호 1 또는 서열번호 3의 아미노산 서열로 구성되는, L-아미노산을 생산하는 코리네박테리움 속 미생물.
- 제1항에 있어서, 상기 프럭토키나제는 서열번호 5의 아미노산 서열로 구성되는, L-아미노산을 생산하는 코리네박테리움 속 미생물.
- 제1항에 있어서, 상기 L-아미노산은 L-라이신(L-lysine) 또는 L-트립토판(L-tryptophan)인, 코리네박테리움 속 미생물.
- 제1항에 있어서, 상기 코리네박테리움 속 미생물은 코리네박테리움 글루타미쿰인, 코리네박테리움 속 미생물.
- 제1항 내지 제5항 중 어느 한 항에 따른 미생물을 배지에서 배양하는 단계; 및 상기 미생물 또는 배지로부터 L-아미노산을 회수하는 단계를 포함하는, L-아미노산의 생산방법.
- 제6항에 있어서, 상기 L-아미노산은 L-라이신 또는 L-트립토판인, L-아미노산의 생산방법.
- 제7항에 있어서, 상기 코리네박테리움 속 미생물은 코리네박테리움 글루타미쿰인, L-아미노산의 생산방법.
- 제1항 내지 제5항 중 어느 한 항에 따른 미생물의 L-아미노산 생산 용도.
- 제1항 내지 제5항 중 어느 한 항에 따른 미생물 또는 상기 미생물의 배양물을 포함하는 L-아미노산 생산용 조성물.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280020233.0A CN117460831A (zh) | 2021-03-08 | 2022-02-21 | 生产l-氨基酸的棒状杆菌属微生物和使用其生产l-氨基酸的方法 |
BR112023018087A BR112023018087A2 (pt) | 2021-03-08 | 2022-02-21 | Micro-organismo do gênero corynebacterium que produz l-aminoácido, método para produzir l-aminoácido, uso da produção do l-aminoácido e composição para produzir l-aminoácido |
MX2023010584A MX2023010584A (es) | 2021-03-08 | 2022-02-21 | Microorganismo del genero corynebacterium para la produccion de l-aminoacido y procedimiento para la produccion de l-aminoacido utilizando el mismo. |
JP2023546556A JP2024505267A (ja) | 2021-03-08 | 2022-02-21 | L-アミノ酸を生産するコリネバクテリウム属微生物及びこれを用いたl-アミノ酸の生産方法 |
AU2022235362A AU2022235362A1 (en) | 2021-03-08 | 2022-02-21 | Microorganism Of The Genus Corynebacterium For Producing L-Amino Acid And Method For Producing L-Amino Acid Using The Same |
EP22767363.9A EP4269598A1 (en) | 2021-03-08 | 2022-02-21 | Microorganism of genus corynebacterium, producing l-amino acids, and method for producing l-amino acids using same |
CA3211373A CA3211373A1 (en) | 2021-03-08 | 2022-02-21 | Microorganism of genus corynebacterium, producing l-amino acid, and method for producing l-amino acid using same |
US18/464,158 US20240043886A1 (en) | 2021-03-08 | 2023-09-08 | Microorganism of the genus corynebacterium for producing l-amino acid and method for producing l-amino acid using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210030087A KR102649245B1 (ko) | 2021-03-08 | 2021-03-08 | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 |
KR10-2021-0030087 | 2021-03-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/464,158 Continuation-In-Part US20240043886A1 (en) | 2021-03-08 | 2023-09-08 | Microorganism of the genus corynebacterium for producing l-amino acid and method for producing l-amino acid using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022191467A1 true WO2022191467A1 (ko) | 2022-09-15 |
Family
ID=83226866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/002505 WO2022191467A1 (ko) | 2021-03-08 | 2022-02-21 | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240043886A1 (ko) |
EP (1) | EP4269598A1 (ko) |
JP (1) | JP2024505267A (ko) |
KR (1) | KR102649245B1 (ko) |
CN (1) | CN117460831A (ko) |
AR (1) | AR125035A1 (ko) |
AU (1) | AU2022235362A1 (ko) |
BR (1) | BR112023018087A2 (ko) |
CA (1) | CA3211373A1 (ko) |
MX (1) | MX2023010584A (ko) |
WO (1) | WO2022191467A1 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0159812B1 (ko) | 1995-12-20 | 1998-11-16 | 손경식 | 코리네박테리움 글루타미컴 씨에이치 77 및 이 균주를 이용한 l-라이신의 제조 방법 |
KR100924065B1 (ko) | 2006-09-15 | 2009-10-27 | 씨제이제일제당 (주) | L-라이신 생산능이 향상된 코리네박테리아 및 그를 이용한 l-라이신 생산 방법 |
US7662943B2 (en) | 2004-12-16 | 2010-02-16 | Cj Cheiljedang Corporation | Promoter sequences from Corynebacterium ammoniagenes |
KR20120111807A (ko) * | 2011-04-01 | 2012-10-11 | 씨제이제일제당 (주) | 에세리키아 속 균주에서 유래된 프락토키나제 유전자가 도입된 코리네박테리움 속 균주 및 상기 균주를 이용하여 l-아미노산을 생산하는 방법 |
KR101208480B1 (ko) | 2003-07-29 | 2012-12-05 | 아지노모토 가부시키가이샤 | 말산 효소 활성이 감쇠된 에스케리키아 세균을 사용하는l-라이신 또는 l-트레오닌의 생산방법 |
US8932861B2 (en) | 2008-04-10 | 2015-01-13 | Cj Cheiljedang Corporation | Transformation vector comprising transposon, microorganisms transformed with the vector, and method for producing L-lysine using the microorganism |
KR102035844B1 (ko) | 2018-02-23 | 2019-10-23 | 씨제이제일제당 주식회사 | L-트립토판을 생산하는 재조합 코리네형 미생물 및 이를 이용한 l-트립토판을 생산하는 방법 |
US10584338B2 (en) | 2016-08-31 | 2020-03-10 | Cj Cheiljedang Corporation | Promoter and use thereof |
-
2021
- 2021-03-08 KR KR1020210030087A patent/KR102649245B1/ko active IP Right Grant
-
2022
- 2022-02-21 JP JP2023546556A patent/JP2024505267A/ja active Pending
- 2022-02-21 CA CA3211373A patent/CA3211373A1/en active Pending
- 2022-02-21 CN CN202280020233.0A patent/CN117460831A/zh active Pending
- 2022-02-21 AU AU2022235362A patent/AU2022235362A1/en active Pending
- 2022-02-21 WO PCT/KR2022/002505 patent/WO2022191467A1/ko active Application Filing
- 2022-02-21 BR BR112023018087A patent/BR112023018087A2/pt unknown
- 2022-02-21 MX MX2023010584A patent/MX2023010584A/es unknown
- 2022-02-21 EP EP22767363.9A patent/EP4269598A1/en active Pending
- 2022-03-07 AR ARP220100505A patent/AR125035A1/es unknown
-
2023
- 2023-09-08 US US18/464,158 patent/US20240043886A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0159812B1 (ko) | 1995-12-20 | 1998-11-16 | 손경식 | 코리네박테리움 글루타미컴 씨에이치 77 및 이 균주를 이용한 l-라이신의 제조 방법 |
KR101208480B1 (ko) | 2003-07-29 | 2012-12-05 | 아지노모토 가부시키가이샤 | 말산 효소 활성이 감쇠된 에스케리키아 세균을 사용하는l-라이신 또는 l-트레오닌의 생산방법 |
US7662943B2 (en) | 2004-12-16 | 2010-02-16 | Cj Cheiljedang Corporation | Promoter sequences from Corynebacterium ammoniagenes |
KR100924065B1 (ko) | 2006-09-15 | 2009-10-27 | 씨제이제일제당 (주) | L-라이신 생산능이 향상된 코리네박테리아 및 그를 이용한 l-라이신 생산 방법 |
US8932861B2 (en) | 2008-04-10 | 2015-01-13 | Cj Cheiljedang Corporation | Transformation vector comprising transposon, microorganisms transformed with the vector, and method for producing L-lysine using the microorganism |
KR20120111807A (ko) * | 2011-04-01 | 2012-10-11 | 씨제이제일제당 (주) | 에세리키아 속 균주에서 유래된 프락토키나제 유전자가 도입된 코리네박테리움 속 균주 및 상기 균주를 이용하여 l-아미노산을 생산하는 방법 |
US10584338B2 (en) | 2016-08-31 | 2020-03-10 | Cj Cheiljedang Corporation | Promoter and use thereof |
KR102035844B1 (ko) | 2018-02-23 | 2019-10-23 | 씨제이제일제당 주식회사 | L-트립토판을 생산하는 재조합 코리네형 미생물 및 이를 이용한 l-트립토판을 생산하는 방법 |
Non-Patent Citations (15)
Title |
---|
"Manual of Methods for General Bacteriology", 1981, AMERICAN SOCIETY FOR BACTERIOLOGY |
APPL. MICROBIOL. BIOTECHNOL, vol. 52, 1999, pages 541 - 545 |
APPL. MICROBIOL. BIOTECHNOL., vol. 52, 1999, pages 541 - 545 |
BECKER, J. KLOPPROGGE, C. HEROLD, A. ZELDER, O. BOLTEN, C.J. WITTMANN, C.: "Metabolic flux engineering of l-lysine production in Corynebacterium glutamicum-over expression and modification of G6P dehydrogenase", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM NL, vol. 132, no. 2, 22 October 2007 (2007-10-22), Amsterdam NL , pages 99 - 109, XP022308433, ISSN: 0168-1656, DOI: 10.1016/j.jbiotec.2007.05.026 * |
BINDER ET AL., GENOME BIOLOGY, vol. 13, 2012, pages 40 |
D. G. GIBSON ET AL., NATURE METHODS, vol. 6, no. 5, May 2009 (2009-05-01) |
DATABASE PROTEIN 28 February 2022 (2022-02-28), ANONYMOUS : "MULTISPECIES: aminoimidazole riboside kinase [Enterobacteriaceae] ", XP055965678, retrieved from NCBI Database accession no. WP_001274885 * |
DATABASE PROTEIN 7 October 2016 (2016-10-07), ANONYMOUS : "Glucose-6-phosphate 1-dehydrogenase [Corynebacterium glutamicum ATCC 13032]", XP055965682, retrieved from NCBI Database accession no. BAB98969 * |
DATABASE PROTEIN 8 June 2021 (2021-06-08), ANONYMOUS : "glucose-6-phosphate dehydrogenase [Corynebacterium glutamicum]", XP055965681, retrieved from NCBI Database accession no. WP_038584208 * |
F. M. AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY |
J. SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
KARLINALTSCHUL, PRO. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
KJELD RAUNKJAER KJELDSEN ET AL., BIOTECHNOL. BIOENG., vol. 102, no. 2, 1 February 2009 (2009-02-01), pages 583 - 97 |
SAMBROOK ET AL., MOLECULAR CLONING, 2012 |
SITNICKA ET AL.: "Functional Analysis of Genes", ADVANCES IN CELL BIOLOGY., vol. 2, 2010, pages 1 - 16 |
Also Published As
Publication number | Publication date |
---|---|
MX2023010584A (es) | 2023-09-22 |
BR112023018087A2 (pt) | 2023-10-03 |
JP2024505267A (ja) | 2024-02-05 |
CN117460831A (zh) | 2024-01-26 |
US20240043886A1 (en) | 2024-02-08 |
KR102649245B1 (ko) | 2024-03-21 |
CA3211373A1 (en) | 2022-09-15 |
AU2022235362A9 (en) | 2024-05-16 |
EP4269598A1 (en) | 2023-11-01 |
AU2022235362A1 (en) | 2023-08-17 |
KR20220126029A (ko) | 2022-09-15 |
AR125035A1 (es) | 2023-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021187781A1 (ko) | 프리페네이트 디하이드라타아제 활성 강화를 통한 l-트립토판을 생산하는 방법 | |
WO2019160301A1 (ko) | 시트레이트 신타아제의 활성이 약화된 변이형 폴리펩타이드 및 이를 이용한 l-아미노산 생산방법 | |
WO2014148743A1 (ko) | 퓨트레신 생산 재조합 미생물 및 이를 이용한 퓨트레신 생산방법 | |
WO2014208970A1 (ko) | 트랜스케톨라아제 유전자 프로모터 변이체 및 이의 용도 | |
WO2019164346A1 (ko) | L-트립토판을 생산하는 재조합 코리네형 미생물 및 이를 이용한 l-트립토판을 생산하는 방법 | |
WO2016148490A1 (ko) | 피루브산 디하이드로게나아제 변이체, 이를 포함하는 미생물 및 이를 이용한 l-아미노산 생산 방법 | |
WO2022163934A1 (ko) | 신규한 d-알라닌-d-알라닌 리가아제 a 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022055094A1 (ko) | L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 | |
WO2022163917A1 (ko) | 신규한 단백질 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2015156583A1 (ko) | L-라이신 생산능을 갖는 미생물 및 이를 이용한 l-라이신 생산 방법 | |
WO2022163935A1 (ko) | 신규한 글루코사민-6-포스페이트 디아미나제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022154191A1 (ko) | 신규한 2,5-다이케토-d-글루콘산 리덕타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022163922A1 (ko) | 신규한 아스파라긴 신타제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022163920A1 (ko) | 신규한 시스테인 설피네이트 디설피나제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022191630A1 (ko) | 신규한 시트레이트 신타아제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022149865A2 (ko) | GlxR 단백질 변이체 또는 이를 이용한 쓰레오닌 생산방법 | |
WO2021242032A1 (ko) | 신규 l-타이로신 배출 단백질 변이체 및 이를 이용한 l-타이로신을 생산하는 방법 | |
WO2022191467A1 (ko) | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 | |
WO2022005022A1 (ko) | L-이소류신 생산능이 강화된 미생물 및 이를 이용한 l-이소류신 생산방법 | |
WO2022163936A1 (ko) | 신규한 엑시뉴클레아제 abc 서브유닛 a 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163941A1 (ko) | 신규한 스퍼미딘 신타아제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163933A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163938A1 (ko) | 신규한 리보뉴클레아제 p 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163940A1 (ko) | 신규한 갈락토사이드 o-아세틸트랜스퍼라제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163937A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-글루탐산 생산 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22767363 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022767363 Country of ref document: EP Effective date: 20230725 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023546556 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2022235362 Country of ref document: AU Date of ref document: 20220221 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3211373 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280020233.0 Country of ref document: CN Ref document number: MX/A/2023/010584 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023018087 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023018087 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230906 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |